Scientific Article
previous document  unige:102148  next document
add to browser collection
Title

Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect

Authors
Grille, Sofía
Moreno, María
Marqués, Juan M
Muñoz, Natalia
Lens, Daniela
Chabalgoity, Jose A
Published in Immunology. 2014, vol. 143, no. 3, p. 428-437
Abstract Despite the efficacy of current immune-chemotherapy for treatment of B-cell non-Hodgkin lymphoma, a substantial proportion of patients relapse, highlighting the need for new therapeutic modalities. The use of live microorganisms to develop anti-tumoural therapies has evolved since Coley's toxin and is now receiving renewed attention. Salmonella Typhimurium has been shown to be highly effective as an anti-tumour agent in many solid cancer models, but it has not been used in haemato-oncology. Here, we report that intra-tumoural administration of LVR01 (attenuated S. Typhimurium strain with safety profile) elicits local and systemic anti-tumour immunity, resulting in extended survival in a lymphoma model. LVR01 induces intra-tumoural recruitment of neutrophils and activated CD8(+) T cells, as well as increasing the natural killer cell activation status. Furthermore, a systemic specific anti-tumour response with a clear T helper type 1 profile was observed. This approach is an alternative therapeutic strategy for lymphoma patients that could be easily moved into clinical trials.
Keywords BacteriaTumour immunologyVaccination
Identifiers
PMID: 24834964
Full text
Article (Published version) (444 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Citation
(ISO format)
GRILLE, Sofía et al. Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect. In: Immunology, 2014, vol. 143, n° 3, p. 428-437. https://archive-ouverte.unige.ch/unige:102148

9 hits

0 download

Update

Deposited on : 2018-02-14

Export document
Format :
Citation style :